Erica L. Mayer, MD, PhD, on Clinical Considerations for New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy in Metastatic Breast Cancer
Posted: Saturday, December 10, 2022
Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses some of the treatment implications based on data from the PACE study of patients with patients with endocrine- and CDK4/6 inhibitor-pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and palbociclib; or fulvestrant, palbociclib, and avelumab. Combining palbociclib with fulvestrant beyond disease progression on prior CDK4/6 inhibitor therapy did not improve progression-free survival compared with fulvestrant alone, but a longer progression-free survival when a PD-L1 inhibitor was added to fulvestrant and palbociclib deserves further study. Dr. Mayer details adverse events of the emerging regimens.